Clinical trial of Qianlie Yikang capsule in the treatment of patients with nonspecific prostatitis
10.13699/j.cnki.1001-6821.2017.13.009
- VernacularTitle:前列益康胶囊治疗非特异性前列腺炎的临床研究
- Author:
Guang-Yuan HE
1
;
Jian-Qi ZHAO
;
Si-Xi ZHANG
;
Ying-Shi SONG
;
Fu-Biao LI
Author Information
1. 吉林大学第一医院药剂科
- Keywords:
Qianlie Yikang capsule;
nonspecific prostatitis;
prostaglandin E2;
interleukin-8
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(13):1198-1200
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect of Qianlie Yikang capsules on the levels of prostaglandin E2 (PGE2) and interleukin-8 (IL-8) in serum and prostatic fluid in patients with nonspecific prostatitis.Methods Eighty patients with nonspecific prostatitis were randomly divided into control group and treatment group,40 cases in each group.Control group was orally given Pule'an tablets 2.0 g,3 times a day.Treatment group was treated with Qianlie Yikang capsules 1.5 g,3 times a day,orally.Before and after treatment,the levels of serum and prostatic fluid PGE2,IL-8 and clinical efficiency in two groups were compared.Results The clinical efficiency of treatment group was 92.50％ (37/40 cases),had significant difference with that in control group,which was 75.00％ (30/40 cases,P ＜ 0.05).After treatment,the serum PGE2 of treatment group and control group were (159.76 ± 16.34),(190.65 ± 17.56) ng · L-1,IL-8 were (2.28 ± 0.32),(3.08 ± 0.22) ng· L-1,with significant difference (P ＜ 0.05).After treatment,the prostatic fluid PGE2 of treatment group and control group were (227.46 ±20.84),(309.46 ± 19.39) ng·L-1,IL-8 were (3.12±0.43),(4.77 ± 0.67) ng · L-1,with significant difference (P ＜0.05).There was no significant adverse reactions in two groups.Conclusion The Qianlie Yikang capsules can significantly reduce the serum and prostatic fluid PGE2,IL-8 levels in patients with nonspecific prostatitis,and have good clinical effect.
